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Introduction
Data from non-clinical and clinical studies have demonstrated
that administration of the synthetic peptide melanocortin
receptor agonists melanotan I or melanotan II can increase skin
pigmentation.[1–4] The mechanism of action of melanotan I is
thought to be mediated by mimicking the effects of endogenous
α-melanocyte stimulating hormone (α-MSH) on the melanocortin
1 receptor that is expressed on melanocytes. This results in the
up-regulation of brown-black eumelanin synthesis, leading to
increased skin pigmentation.[5,6] Melanotan II, a cyclic, lactam-
bridged heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-
Phe-Arg-Trp-Lys]-NH2, is thought to exert a comparable action;
however, data are limited as clinical studies of this peptide in
human skin pigmentation were not pursued after it was found to
induce penile erection.[1,7–11] Nevertheless, skin-tanning products
that claim to contain melanotan II are being advertised and sold
on the illicit drug market. This includes through Internet shops as
well as being sold and administered in gyms, hairdressers, tanning
salons, and beauty salons.[12,13]
Most of the information about the sale and use of these prod-
ucts comes from regulatory action against retailers, seizures
made by police and custom authorities, Internet monitoring of
shops and user discussion forums, case reports/series of
suspected adverse reactions, and media reports. Triangulation
of this information suggests that over the past few years the
use of melanotan II has been growing amongst people who want
to increase their skin pigmentation usually for cosmetic reasons;
to a lesser degree the drug is also used for weight loss, as an
aphrodisiac, and as a self-directed treatment for diseases such
as rosacea.[12,13]
Medicine regulatory authorities in a number of countries in
Europe as well as Australia and the United States have classed
such ‘melanotan products’ as unauthorized medicinal products.
As a result, marketing, distribution, and advertisement are unlaw-
ful without authorization in these jurisdictions. Warnings have
been issued related to the sale and use of these products,[14–17]
with the Medicines and Healthcare Products Regulatory Agency
in the United Kingdom closing down 72 online shops in mid-
2013.[16] Even so, a search for ‘buy melanotan’ on Google, that
we conducted at the time of writing this paper, found a number
of online shops selling products claiming to contain melanotan II,
and, to a lesser degree, melanotan I.
The acute adverse reactions associated with administration of
melanotan II reported from phase I and II clinical studies include
spontaneous erections, facial ﬂushing, nausea, and vomiting.[8,9,18]
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New methods were developed and validated to determine the identity, contents, and purity of samples of melanotan II, a 
synthetic melanocortin receptor agonist, sold in vials as injectable skin-tanning products that were purchased from three 
online shops. Methods were based on liquid chromatography with ultra-violet detection (LC-UV) at wavelength 218 nm, 
and tandem mass spectrometric detection (MS/MS) after collision-induced fragmentation of the double charged [M+2H]2+ 
precursor ion (m/z 513). Identiﬁcation of melanotan II was veriﬁed by correct chromatographic retention time, and relative 
abundance ratios of ﬁve qualifying fragment ions. LC-UV was used to quantify melanotan II as well as impurities. Method 
validation was performed with reference to guidelines for assessing active substances in authorized medicinal products to 
reach acceptable accuracy and precision. Vials from two shops contained unknown impurities ranging from 4.1 to 5.9%; 
impurities from one shop were below the quantiﬁcation limit. The total amount of melanotan II in vials ranged between 
4.32 and 8.84 mg, although each shop claimed that vials contained 10 mg melanotan II. A broad range of drugs used for 
enhancement purposes can be obtained from the illicit market. However, users of these drugs may be exposed to a range 
of potential harms, as shown in this study, given that these products are manufactured, distributed and supplied from an illicit 
market. Copyright © 2014 John Wiley & Sons, Ltd.
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Little is known about the potential for chronic adverse reactions,
although there are obvious concerns given that melanotan II is a
potent non-selective melanocortin receptor agonist with high
afﬁnity for MC1, MC3, MC4, and MC5 receptor subtypes –
which are involved in the regulation of a number of physiolog-
ical systems such as the pigmentary system, energy
homoeostasis, sexual functioning, the immune system, inﬂam-
mation, and the cardiovascular system.[19] Suspected adverse
reactions associated with the use of melanotan or melanotan
II bought from the illicit market have been reported through
national pharmacovigilance systems and clinical case
reports.[20–29] These include changes in pre-existing moles (such
as dysplastic growth) and one case of systemic toxicity.[29] However,
causal assessment of most of these cases is, in part, confounded by
a lack of analytical identiﬁcation of the actual substance used
(either from toxicological screening of a biological sample from
the patient or forensic analysis of the product used). In this respect,
as far as we are aware, analytical conﬁrmation of the substance
used – melanotan II – was only reported in the case report of
systemic toxicity.[29]
Additional hazards posed by the use of these products arise
from the fact that they are administered by injection. As a result
users may be exposed to non-sterile products and/or other forms
of product contamination; while from a broader public health
perspective the sharing of injecting equipment and/or drug vials
can transmit bacterial as well as viral infections such as HIV,
hepatitis B, and hepatitis C.
In previous research, analytical methods have been used to
characterize melanotan I and melanotan II in biological samples
from animals and humans. One study used liquid chromatogra-
phy with ultra-violet detection (LC-UV) to quantify melanotan II
in rat plasma.[30] In other studies, liquid chromatography-tandem
mass spectrometry (LC-MS/MS) was used to quantify melanotan II
in plasma and brain tissue in mice[31] and in rat plasma.[32]
Another study used LC-UV to quantify melanotan I in human
plasma, although the recovery and sensitivity was low.[33] These
methods are not directly applicable for analysing lyophilized
solids in drug vials. One study used MS to identify melanotan II
in samples seized by law enforcement agencies, although details
of the applied methods were not provided.[34]
No published validated analytical methods are currently
available to identify and quantify active substance and impurities
of products claiming to contain melanotan II. As melanotan II are
produced outside formal regulatory systems and thus without
the necessary quality assurance systems, methods to determine
their composition are needed to assess their potential health haz-
ards. This need was further highlighted to us when the substance
from an unlabelled vial, seized from a drug treatment
programme in Denmark, was analyzed by our group and found
to contain melanotan II.[35]
The present study aimed at developing, validating, and apply-
ing analytical methods for melanotan II products, based on liquid
chromatography with ultraviolet detection and tandem mass
spectrometry (LC-UV-MS/MS). Data are presented from analysis
of products claiming to contain melanotan II that were purchased
from three online shops. Results include identiﬁcation of the ac-
tive substance, total content of active substance in vials (mg)
and unknown impurities (area-%). While a small number of stud-
ies have identiﬁed melanotan II in vials seized by law enforce-
ment agencies,[34] and substances used by patients,[29,35] as far
as we know, these are the ﬁrst published quantitative data based
on a validated analysis of melanotan II.
Methods and materials
Sample acquisition
In mid-2011, the term ‘buy melanotan’ was used to search
google.co.uk for online shops that were selling ‘melanotan’
skin-tanning products. The search gave a ranked list of websites
based on importance/relevance determined by Google which is
likely to provide measure of the popularity of these sites amongst
consumers looking to buy these products.[36,37] Each hyperlink to
a website was followed to select shops that: (1) claimed to offer
vials with 10 mg of melanotan II; (2) accepted credit card
payment through a secure website; and (3) offered delivery to
the United Kingdom. Three shops that met the inclusion criteria
were then selected from the ﬁrst 20 results. A total of 73 vials
were purchased from the shops, hereafter referred to as Shop
A, Shop B, and Shop C (Table T11). While it is difﬁcult to determine
whether these shops were different storefronts for the same
retailer, an examination of the websites (e.g. comparing shop
contact information and packaging/labelling of the products),
suggests that this did not appear to be the case.
On receipt of the products, the contents of each package were
inspected by us to document the contents including the number
of vials that were provided. The vials were then shipped to the
Department of Clinical Biochemistry (Vendsyssel Hospital,
Table 1. Melanotan II product information, contents of melanotan II
in vials (mg) and sum of impurities (area-%)
Internet
shop and
product
numbera
Total content
of melanotan II
in vial (mg)
Mean (mg);
% RSD
Sum of
impurities
(area-%)
Mean
(area-%); %
RSD
A1 4.70 4.91; 2.2 4.7 4.5; 4.9
A2 4.83 4.8
A3 5.03 4.3
A4 4.90 4.6
A5 4.89 4.7
A6 4.96 4.1
A7 5.12 4.3
A8 4.82 4.6
A9 4.78 4.2
A10 4.81 4.7
A11 4.99 4.7
A12 4.92 4.3
A13 4.97 4.6
A14 4.95 4.6
A15 4.97 4.4
B1 6.06 7.08; 14.5 4.9 5.03; 9.2
B2 7.73 5.1
B3 6.67 4.6
B4 6.50 4.7
B5 8.84 5.0
B6 6,67 5,9
C1 4.32 5.20; 10.1 < 0.05 N/A
C2 5.13 < 0.05
C3 5.58 < 0.05
C4 5.58 < 0.05
C5 5.40 < 0.05
aTotal number of vials purchased from each shop; Shop A, n=32;
Shop B, n=21; Shop C, n=202
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Denmark). Upon arrival, each vial was labelled with a unique
identiﬁer, and vials from each retailer were assigned to three
different studies. This paper reports on the analysis of 26 vials.
All vials were stored at room temperature in the dark. Analysis
commenced within one week of arrival in Denmark. The study
had approval from the Danish Health and Medicines Authority.
Reference standards and chemicals
Melanotan II reference standards (CAS number: 121062-08-6)
were purchased from Sigma-Aldrich (Munich, Germany), Tocris
Bioscience (Bristol, UK), and Bachem (Bubendorf, Switzerland).
All melanotan II standards used in this study were prepared in
aqueous solutions. For all quantitative data shown below, the
‘industrial grade’ standard from Sigma-Aldrich (Cat. No. M8693)
was assigned as primary calibration standard. Triﬂuoroacetic acid
(TFA), used for preparation of mobile phase A, was LC grade from
Thermo Scientiﬁc (Loughborough, UK). Acetonitrile with 0.1%
TFA (mobile phase B) was LC-MS grade from Fluka (Buchs,
Switzerland). Ultrapure water (18.2 MΩ) used for preparation of
standards, samples, blanks and mobile phases was prepared on
an Elga Centra RDS system (Buckinghamshire, United KingdomQ2 ).
A Mettler Toledo analytical scale (Greifensee, Switzerland) was
used to prepare standard solutions for reference.
Sample preparation
An aqueous stock of each sample was prepared by adding
ultrapure water to the vial through a 5 mL syringe. The syringe
was ﬁlled with 1.00 mL water, using a calibrated pipette, and its
content transferred to the vial using a surplus of air. From this
solution, an aliquot of 100 μL was transferred to a micro vial for
determination of impurities by LC-UV. Another 50 μL was diluted
with 450 μL water and 100 μL transferred to a micro vial for assay
by LC-UV to determine the vial’s content (mg). Finally, 50 μL of
the remaining assay solution was diluted with 950 μL water, and
used for unambiguous identiﬁcation of melanotan II by LC-UV-MS/MS.
Instrumentation and conditions
Chromatography
LC was performed using Agilent Technologies 1200 series LC
modules (Waldbronn, Germany). Auto sampler injection volume
was set to 10 μL for detection of impurities, otherwise to 1 μL.
The analytical column was an Agilent Zorbax 300SB-C8, 100
mm x 2.1 mm i.d., packed with 3.5 μm particles. Flow rate was
450 μL/min. Column temperature was 50°C. Mobile phase A
was 0.1 % TFA in aqueous solution. Mobile phase B was 0.1%
TFA in acetonitrile. The binary pump gradient went from 5% B
for 0.1 min to 95% B in 7 min, where it was maintained for 2
min, and was brought back to equilibration at initial conditions
for 3 min. Total run time: 15 min. UV detection was performed
using an Agilent 1100 diode array detector. Wavelength was
218 nm; bandwidth 30 nm; slit width 16 mm; and sampling rate
0.62 Hz with no reference wavelength.
Mass spectrometry
The MS/MS after electrospray ionization was performed on a
Sciex QTRAP 3200 mass spectrometer (Applied Biosystems,
USQ3 A) equipped with a Turbo Ion Source (electrospray) operated
in positive mode. Parameters for MS/MS were optimized during
infusion of a melanotan II reference standard solution using the
Analyst 1.5 software. Ion spray voltage was set to 2500 V; source
temperature: 550°C; ion gas 1: 55 p.s.i.; ion gas 2: 50 p.s.i.; curtain
gas: 22 p.s.i.; and declustering potential was 81 V. Multiple reac-
tion monitoring (MRM) parameters and collision energies (CE)
for the six collision induced dissociations were m/z 513 → m/z
86.0 (CE: 59), 110.1 (CE: 59), 83.8 (CE: 59), 70.4 (CE: 61), 120.1
(CE: 61) and 130.1 (CE: 61), listed in order of decreasing relative
intensity. Dwell time was 150 ms at unit resolution.
Method validation
The validation was based in part on the international conference
of harmonization of technical requirements for registration of
pharmaceuticals for human use (ICH) guideline TOPIC Q2
(R1).[38] Acceptance criteria are listed in Table T22. Intermediate
precision was not tested.
Assay method
Linearity for the assay method was assessed by analysis of ﬁve
melanotan II standard solutions prepared by diluting an aqueous
stock solution of melanotan II (Sigma-Aldrich, Cat. No. M8693) to
0.205, 0.41, 0.82, 1.23 and 1.64 mg/mL. Linear regression analysis
was performed on the basis of peak areas with no weighting fac-
tor and curves not forced through origin. Accuracy and precision
was assessed by determination of method recovery (%) and rela-
tive standard deviation (% RSD) at 80, 100 and 120% from the tar-
get value for assay (0.82 mg/mL). System precision was expressed
as % RSD from ﬁve injections of a 0.82 mg/mL standard.
Method for impurities
Linearity was assessed by analysis of six melanotan II standard so-
lutions in the range 3.28 μg/mL to 205 μg/mL prepared by dilut-
ing an aqueous stock solution of melanotan II (Sigma-Aldrich, Cat.
No. M8693). Linear regression analysis was performed from peak
areas with no weighting factor and not forced through origin. To
determine accuracy and precision at the required limit of quanti-
ﬁcation, ﬁve different standard solutions at 4.1 μg/mL (equal to
0.05% of the target concentration: 8.2 mg/mL) were analyzed.
Limit of detection was deﬁned as the concentration at which
the peak signal-to-noise ratio was above ﬁve. Impurities were
reported in area-% of the base peak (melanotan II) in the chro-
matogram. This practise is generally applied in pharmaceutical
analysis of unknown impurities in medical products.
Identiﬁcation by MS/MS
Melanotan II was identiﬁed in samples by LC retention time (± 0.5 min
relative to standard) and six fragment ions after collision induced
dissociation of the double charged [M+H]2+ molecular ion (m/z
513). These ions are either speciﬁc immonium fragments from
amino acid side chains of norleucine, histidine, phenylalanine and
tryptophane, or ions related to the amino acids in melanotane
II[39] as seen in the product ion spectrum of m/z 513 (Figure F11).
For unambiguousmass spectral identiﬁcation of melanotan II, the
relative ion intensities of ﬁve qualifying ions, expressed as the per-
centage of the intensity of the most intense MRM transition (m/z
513→m/z 86), must be within ± 20% compared to averaged values
for calibrators (n=3) in the same analytical sample run.[40] The accep-
tance criteria were tested for multiple injections of samples (n=5).
Stability study of standards and samples
Short-term stability was assessed by placing a standard and sample
solutions in vials (1 mL, 0.82 mg/mL) at 4°C in dark, -22°C in dark
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and in light by room temperature. After 48 h, the peak response at
218 nmwas compared to a new and recently prepared Sigma stan-
dard (0.82 mg/mL). The acceptance criterion for response (peak
area) change was ± 5%. No forced stability studies were conducted.
Analysis of other reference standards
The Sigma-Aldrich standard stock solution (0.82 mg/mL) was
used to quantify the two other commercially available reference
standards (Tocris and Bachem) using the assay method with
triplicate injections of each standard in 1 mg/mL solutions of
the white, lyophilized solids. The stated peptide content on the
respective certiﬁcates of analysis was used to compare the quan-
titative results.
Results and discussion
Method development
During method development in the present study, a number of
anionic ion pairing reagents were tested unsuccessfully as mobile
phase modiﬁers, including formic acid, acetic acid, and
heptaﬂuorobutyric acid. The latter has been found useful in
reversed-phase separations of proteins and peptides.[41] However,
only TFA as a mobile phase modiﬁer could produce chromato-
grams with symmetric, non-tailing peaks by LC-UV (FigureF2 2). Gradi-
ent elution was chosen to achieve optimal conditions for
separation of impurities. The spectrum of melanotan II in the
mobile phase showed a local absorbance optimum at 218 nm,
which was used as detection wavelength to ensure that the sensi-
tivity criterion was met.
Method validation results
The method validation data for precision, accuracy, sensitivity,
and stability were acceptable for the purpose of the study
(Table 2). Retention time varied more than ± 0.5 min between dif-
ferent preparations of mobile phases, but retention time was al-
ways within ± 0.03 min for standards and conﬁrmed melanotan
II samples in analytical series. Blanks were free from interfering
signals (Figure 2). It was concluded that standards and samples
were fully stable in solution within the time frame of analysis
(48 h).
Limitations of the methods
The ICH guideline Topic Q2 (R1) lists standards for identiﬁcation
as well as quantitative testing of active substances, and impuri-
ties for registration applications for new drugs submitted within
the European Union, Japan, and the United States.[38] Synthetic
peptides for medical treatment, however, fall between high
molecular weight biopharmaceuticals and classical organic mole-
cules for which ICH regulatory guidelines do not apply directly,[42]
and there is no compendial monograph available for melanotan
II. Certain criteria of the ICH guideline could not be met in this
study (Table 2). For example, synthetic by-products and degrada-
tion products for melanotan II are not available as reference com-
pounds and their response factors are unknown. The impurities
Table 2. Validation data and ICH guidelines acceptance criteria for methods of identiﬁcation, assay and impurities
Method and parameter Acceptance criteria Results in this study
IDENTIFICATION
Retention time Retention time should match
calibration standards within ± 0.5 min
All samples within ± 0.03 min
Mass spectral data The relative ion intensities of 5 qualifying
MRM transitions should match the average
of reference standards (n=3) in the analytical
sample run within ±20%
All relative ion intensities for qualifying ions within ± 10%
ASSAY
Linearity Correlation coefﬁcient, r ≥ 0.995 r = 0.9993
Range No criteria. For information only 0.205–1.64 mg/mL
Accuracy and precision Mean recovery: 100 ± 2% at 80–100%
of target sample concentration
(0.82 mg/mL), n=5.
Level Recovery (%) RSD
(%)
80% 101 1.65
100% 100 0.75
120% 99 1.62
System precision ≤ 2 % RSD for n=5 injections RSD = 0.79%
Stability (standard /sample)
48 hours
Change in response of 0.82 mg/mL
solution ≤ 5%
< 2.1%
IMPURITIES
Linearity Correlation coefﬁcient, r ≥ 0.995 r = 0.9997
Range No criteria. For information only 4.1–205 μg/mL
Accuracy Mean recovery: 100 ± 20% at 0.05% 100%
Precision RSD-% ≤ 10 % at 0.05% of base peak (n=5) 0.39%
Limit of quantiﬁcation 0.05% 4.1 μg/mL (or 0.05%)
Limit of detection No criterion. For information only 3 μg/mL (or 0.03%)
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detected in this study were not fully separated from the base
peak. It is questionable whether a full separation can be achieved
by reversed-phase chromatography. Furthermore, impurities that
co-elute with the base peak will not be detected with the
methods presented here. Quantiﬁcation of impurities was based
on careful, manual integration of peak areas using the tangent
skimming method. No attempts were made to determine the
presence of salts, residual solvents, and water in samples. Hence,
this study only reports organic compounds detectable with LC-UV
at 218 nm as impurities.
Moreover, the ICH guidelines apply to substances that are pro-
duced under strict supervision to meet speciﬁcations for active
substances and consistency in each batch. In contrast, melanotan
II products obtained from online shops are manufactured outside
of formal regulatory systems. Consequently, vials purchased from
the same shop could have been manufactured differently, for
example originating from different synthetic routes or produced
in different manufacturing plants/laboratories resulting in varia-
tion in content.
Finally, it should be noted that methods developed in this
study do not apply to biological samples.
Reference standards
All three analytical grade standards purchased for the study
stated the peptide purity on their respective certiﬁcates of analy-
sis. No impurities were detected in the Sigma (peptide content:
82%), Tocris (peptide content: 69.4%), or Bachem standard
(peptide content: 88.4%). Quantiﬁcation of the Tocris and
Bachem standard, relative to the Sigma standard, showed
Figure 2. LC-UV assay method showing (a) chromatogram (218 nm) of a Sigma-Aldrich Melanotan II standard; (b) blank sample.
Figure 1. Product ion spectrum of the double charged [M+2H]2+ precursor ion (m/z 513) of melanotan II standard using direct sample infusion at 10 "l/
min. The spectrum is dominated by immonium ions of norleucine (m/z 86, label: I), histidine (m/z 110, label: H), phenylalanine (m/z 120, label: F),
tryptophane (m/z 159, label: W) and related ions characteristic of arginine (m/z 70) lysine (m/z 84) and tryptophane (m/z 130). Above m/z 300 only ions
with very low abundances were observed due to the high level of collision energy (CE: 55). The immonium ions of lysine (m/z 101) and aspartic acid (m/z
88) are not observed as these are lactam-bridged in melanotan II.
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deviations from the theoretical value of +1.0% and +1.1%,
respectively, which is within the method imprecision. Thus, it
was concluded that all three chemical standards were quantita-
tively compatible.
Application to melanotan II products
Assay and impurities
For all standards and samples the relative ion intensity ratios mea-
sured by MS/MS were within the acceptance criteria of ± 20%.
Accordingly, it was concluded that all sample vials contained
melanotan II. The total amount of melanotan II in the vials ranged
from 4.32 to 8.84 mg.
The UV chromatographic proﬁles of melanotan II products
from Shop A and Shop B (FigureF3 3) showed impurities between
4.1 to 5.9% (Table 1), whereas impurities in samples from Shop
C were below the quantiﬁcation limit. Methods applied in this
study neither identify nor discriminate between impurities from
synthesis, degradation products, or contaminants.
Vials and supplied accessories
Shop A only supplied vials of melanotan II. None of these had any
form of marking to identify the active substance (FigureF4 4 shows
pictures of vials from all three shops). Of note is that we
discovered that a vial from Shop A had a damaged metal overseal
(a small but visible dent) suggesting that future studies should
undertake sterility testing of products from the illicit market.
Shop B supplied vials, alcohol skin wipes, injecting equipment,
as well as an unlabelled excipient. Vials from Shop B were
unmarked. Shop C supplied vials, alcohol skin wipes, injecting
equipment, as well as a vial of excipient labelled ‘bacteriostatic
water’. Here it appeared that the shop had produced labels for
their vials of melanotan II (labelled ‘MT2 Melanotan Powder’)
using the same branding as the website from which they were
sold. Products from Shop C were delivered with instructions that
provide dosage regimens as well as instructions on how to inject
the product. This, along with testimonies from ‘satisﬁed
customers’ posted on the websites of retailers, may go some
way towards legitimizing these products and their use. It is
notable that samples bought from Shop C had a sticker on the
packages with the words: ‘Item checked’. It is possible that such
marketing techniques are used to give the products an air of
authenticity and quality.
Implications for user safety and public health
Although each of the tested vials contained a lower amount
(4.32–8.84 mg) of melanotan II than the 10 mg claimed on the
shops’ websites, it is important to highlight that the results from
this study should not be generalized beyond this sample; users
cannot assume that other melanotan II products are under
strength and should not subsequently increase the dose used
as a result of these ﬁndings.
High levels of impurities were detected in samples from Shop
A and Shop B; while from Shop C they were below the limit of
quantiﬁcation. Since most users inject melanotan II, the presence
Figure 3. Examples of LC-UV impurity proﬁles of (a) products from Shop A; (b) products from Shop B; (c) products from Shop C; (d) data for Sigma
melanotan II standard showing the six overlaid MRM transitions (m/z 513→m/z 86, 110, 84, 70, 120 and 130) used for mass spectrometric identiﬁcation.
Arrows indicate those impurities which are quantiﬁed in Table 1.
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of impurities may pose a hazard. Further work is required in or-
der to characterize these impurities as well as the hazards that
they pose.
A broad range of substances and medicinal products used for
enhancement purposes can be obtained without prescription
from online shops, bricks-and-mortar shops, and dealers. These
include products such as melanotan II which are primarily used
to increase skin pigmentation, as well as those used to enhance
muscle, cognitive function, modify mood and social behaviour,
lose weight, and stimulate sexual function.[13] However, users
may be exposed to a range of potential harms from such
products, as highlighted in this study, in part because the manu-
facturers of these substances are usually beyond of regulatory
oversight Q4. The transnational nature of the global market of
enhancement drugs makes it particularly difﬁcult to control and
reduce supply. In part this appears to be due to the growing role
of the sale of such drugs through the Internet. In the latter case
this is as the legal regulation of the Internet is largely based on
national law whereas manufacturers, suppliers, retailers, website
hosting and payment processing services may all be based in dif-
ferent countries. In addition, there are often few restrictions on
consumers buying these drugs for their own use.[13]
Melanotan II is just one of a growing range of human enhance-
ment drugs being sold illegally both online as well as through
bricks-and-mortar shops and street-level dealers. While it is not
yet possible to estimate the potential for acute and chronic
Figure 4. Melanotan II products. (a) vials from Shop A, Shop B and Shop C (from left to right); (b) products from Shop C and ‘bacteriostatic water’; (c)
‘Tanning injection leaﬂet’ with information on dosage supplied with vials from Shop C; (d) an example of a vial delivered from Shop B with alcohol wipes,
excipient (unlabelled), and injecting equipment; (e) unlabelled vials from Shop A shown after being unwrapped from a cushioned envelope.
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health harms of many of these enhancement drugs, including
melanotan II, analytical methods such as those provided in this
study play an essential role in the public health response to these
drugs by proving tools to identify and quantify the active sub-
stance and impurities. In turn this helps develop both our under-
standing of composition of such drugs and their quality, and,
from this, some of the hazards that they may pose.
Conclusions
Analytical methods to unambiguously identify melanotan II,
quantify vial content and determine the level of impurities were
developed and validated. Furthermore, this study demonstrated
for the ﬁrst time that melanotan II is readily available on the illicit
market, being identiﬁed in all vials that were tested.
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